ArticleJHEP reports : innovation in hepatology2025
Serum fibrosis marker M2BPGi-based novel score predicts survival of unresectable HCC undergoing immunotherapy.
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimal treatment selection for hepatocellular carcinoma in the era of immunotherapy.Journal of gastroenterology · 2026Review
- Secretory LGALS3BP exacerbates sepsis-associated liver dysfunction by activating inflammasome-mediated pyroptosis.Cell death discovery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Most patients with hepatocellular carcinoma (HCC) have underlying chronic liver disease, which may influence survival outcomes. Mac-2 binding protein glycosylation isomer (M2BPGi) is a biomarker reflecting liver fibrosis status, which in turn may be associated with survival in patients with HCC treated with immune checkpoint inhibitors (ICIs), particularly in regions where viral hepatitis is endemic. Methods: From September 2017 to September 2022, 158 patients receiving ICIs for unresectable HCC were prospectively enrolled, and baseline serum samples were collected for M2BPGi measurement. Variables associated with overall survival (OS) were analyzed. An additional 60 consecutive patients with unresectable HCC were recruited after October 2022 for validation. Results: In the training cohort, serum M2BPGi level correlated strongly with Fibrosis-4 score, Child-Pugh class and ALBI (albumin-bilirubin) grade. An M2BPGi ≥1.68 COI (cut-off index) was associated with significantly reduced OS (hazard ratio 1.992, 95% CI 1.369-2.900; Conclusion: Serum fibrosis marker M2BPGi correlates with liver reserves and survival in patients with HCC undergoing ICI-based immunotherapy. The newly developed Mac-2 score may offer improved clinical utility in this population. Impact and implications: Most cases of hepatocellular carcinoma occur in patients with underlying liver fibrosis or cirrhosis, and the fibrotic microenvironment may influence the anti-tumor effects of immune checkpoint inhibitors. Serum M2BPGi reflects liver fibrosis status and liver reserve in hepatocellular carcinoma and is associated with survival outcomes in patients receiving ICI-based immunotherapy. The novel Mac-2 score, based on baseline M2BPGi levels, has the potential to enhance patient selection and guide therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.